- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 7/62 - PolymyxinesPeptides apparentés
Détention brevets de la classe C07K 7/62
Brevets de cette classe: 121
Historique des publications depuis 10 ans
|
16
|
10
|
13
|
11
|
11
|
10
|
5
|
11
|
4
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Xellia Pharmaceuticals ApS | 91 |
10 |
| Spero Therapeutics, Inc. | 49 |
9 |
| Monash University | 704 |
8 |
| Northern Antibiotics Oy | 9 |
8 |
| New Pharma Licence Holdings Limited | 4 |
4 |
| Northern Antibiotics Ltd. | 6 |
4 |
| Shanghai Micurx Pharmaceutical Co., Ltd. | 17 |
4 |
| Cidara Therapeutics, Inc. | 70 |
3 |
| MicuRx Pharmaceuticals, Inc. | 9 |
3 |
| Universiteit leiden | 189 |
3 |
| Universitat de Barcelona | 280 |
3 |
| Spero Therapeutics, Inc. | 3 |
3 |
| The Regents of the University of California | 19812 |
2 |
| The Trustees of Columbia University in the City of New York | 3558 |
2 |
| Purdue Research Foundation | 3564 |
2 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 690 |
2 |
| Helperby Therapeutics Limited | 63 |
2 |
| Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences | 74 |
2 |
| Shanghai Institute of Pharmaceutical Industry | 129 |
2 |
| Universidad de Barcelona | 97 |
2 |
| Autres propriétaires | 43 |